KYTX trades 301.9% below Wall Street's consensus target of $25.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes KYTX achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 4 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of October 3, 2026, Kyverna Therapeutics, Inc. (KYTX) has a Wall Street consensus price target of $25.00, based on estimates from 4 covering analysts. With the stock currently trading at $6.22, this represents a potential upside of +301.9%. The company has a market capitalization of $378M.
Analyst price targets range from a low of $25.00 to a high of $25.00, representing a 0% spread in expectations. The median target of $25.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 4 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, KYTX trades at a trailing P/E of -1.7x. Analysts expect EPS to grow -10.2% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 CABACabaletta Bio, Inc. | $326M | $2.00 | $16.33 | +716.5% | Buy | — | 12 |
 AUTLAutolus Therapeutics plc | $474M | $1.78 | $8.87 | +398.3% | Buy | — | 14 |
 IMVTImmunovant, Inc. | $6.9B | $33.62 | $40.00 | +19.0% | Buy | — | 23 |
 BEAMBeam Therapeutics Inc. | $2.5B | $24.50 | $59.50 | +142.9% | Buy | — | 27 |
 LEGNLegend Biotech Corporation | $3.4B | $18.57 | $61.43 | +230.8% | Buy | — | 20 |
 CRSPCRISPR Therapeutics AG | $5.3B | $55.43 | $67.83 | +22.4% | Buy | — | 38 |
 NTLAIntellia Therapeutics, Inc. | $1.4B | $12.26 | $23.00 | +87.6% | Buy | — | 39 |
 EDITEditas Medicine, Inc. | $402M | $2.62 | $4.50 | +71.8% | Buy | — | 26 |
 FATEFate Therapeutics, Inc. | $270M | $2.32 | $5.63 | +142.7% | Buy | — | 31 |
 ALLOAllogene Therapeutics, Inc. | $518M | $1.50 | $6.43 | +328.7% | Buy | — | 30 |
Quick answers to the most common questions about buying KYTX stock.
The consensus Wall Street price target for KYTX is $25, representing 301.9% upside from the current price of $6.22. With 4 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
KYTX has a consensus rating of "Buy" based on 4 Wall Street analysts. The rating breakdown is predominantly bullish, with 4 Buy/Strong Buy ratings. The consensus 12-month price target of $25 implies 301.9% upside from current levels.
KYTX's current price is $6.22 with a consensus target of $25 (301.9% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $25 for KYTX, while the most conservative target is $25. The consensus of $25 represents the median expectation. These targets typically reflect 12-month expectations.
KYTX is lightly followed, with 4 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month KYTX stock forecast based on 4 Wall Street analysts shows a consensus price target of $25, with estimates ranging from $25 (bear case) to $25 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on KYTX, with a "Buy" consensus rating and $25 price target (301.9% upside). 4 of 4 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
KYTX analyst price targets range from $25 to $25, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $25 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.